Graphite backed Random42 to continue its rapid growth as the leading global 3D and Virtual Reality animation and digital media services provider to the healthcare and pharmaceutical industries

Random42 produces scientific digital animations and experiences to assist pharmaceutical and biotech companies communicate highly complex messages in an easy-to-understand format to a wide range of stakeholders. Animations, which are typically in a 3D, Virtual Reality or Augmented Reality format, are used for educational and promotional purposes throughout the lifecycle of healthcare products, from the pre-clinical stage through to clinical trials, and as part of product launches and refreshes.

The company employs a combination of highly skilled animators, software developers and scientists, enabling it to generate high-quality, scientific animations, which demonstrate disease mechanisms and the ways in which molecular medical and pharmaceutical products interact with the human body. Random42 works directly with the vast majority of the top 25 pharmaceutical companies worldwide, including AstraZeneca, BMS, GSK, Merck, Novartis, Pfizer and Roche, and has relationships across Europe, the US and Asia. 

Graphite is supporting Random42 in its continued professionalisation and international expansion. With scalable account management and a proactive sales and marketing strategy, there is significant scope for deeper customer and market penetration. We also believe there are exciting opportunities to diversify into adjacent markets, capitalising on the company’s historical success of combining scientific knowledge with outstanding production quality. The company has been relatively unaffected by Covid-19 and should be well placed to capitalise on the growing trends towards digital distribution and remote learning within life sciences. Illustrating the relevance of the company’s digital products, Random42 has worked on eight separate Covid-19 animations.